PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
27.06%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
-304.05%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-302.06%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-288.66%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.11%
Share reduction more than 1.5x AGEN's 11.06%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.68%
Diluted share reduction more than 1.5x AGEN's 11.06%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
56.08%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
56.11%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-17391.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-1778.39%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-42866.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-15208.07%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-5247.61%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
4590.00%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
1682.71%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1405.22%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
247.25%
BV/share growth above 1.5x AGEN's 9.12%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-50.51%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-53.09%
Our R&D shrinks while AGEN invests at 29.87%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.56%
SG&A declining or stable vs. AGEN's 60.57%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.